Ophthalmic components

Incorporating sesame oil, castor oil, or liquid paraffin with menthol and ultrasound in ophthalmic compositions stabilizes oil-in-water emulsions, addressing the stability challenge in surfactant-free formulations.

JP2026182834APending Publication Date: 2026-11-19ROHTO PHARM CO LTD +1
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2026078445
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-07
Filing Date
2026-05-07
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Existing ophthalmic compositions with reduced or no surfactant content face challenges in stabilizing oil-in-water emulsions over time.

Method used

Incorporating sesame oil, castor oil, or liquid paraffin with menthol, and optionally vitamins A and E, and irradiating the mixture with ultrasound to enhance the stability of oil-in-water emulsions.

Benefits of technology

Improves the temporal stability of ophthalmic compositions without surfactants by maintaining emulsion integrity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2026182834000001_ABST
    Figure 2026182834000001_ABST
Patent Text Reader

Abstract

To provide an ophthalmic composition that exhibits improved long-term emulsification stability even without substantially containing surfactants. [Solution] An ophthalmic composition comprising an oil-in-water emulsion, wherein the oil-in-water emulsion comprises (A) one or more selected from the group consisting of sesame oil, castor oil, and liquid paraffin, and (B) a terpenoid.
Need to check novelty before this filing date? Find Prior Art

Description

TECHNICAL FIELD

[0001] The present invention relates to an ophthalmic composition. BACKGROUND ART

[0002] In general, when preparing an ophthalmic composition such as an eye drop containing a poorly soluble substance, a surfactant is used to emulsify the poorly soluble substance to obtain a formulation in which an emulsion is formed.

[0003] As ophthalmic compositions with a reduced surfactant content, ophthalmic compositions prepared by high-pressure emulsification or ultrasonic emulsification are known (for example, Patent Document 1). It is also known that the stability of an oil-in-water emulsion can be improved without adding a surfactant by adding alcohols such as ethanol and glycerin (for example, Patent Document 2). PRIOR ART DOCUMENTS PATENT DOCUMENTS

[0004] PATENT DOCUMENT 1 Japanese Unexamined Patent Publication No. 2002-332225 PATENT DOCUMENT 2 Japanese Unexamined Patent Publication No. 2019-198866 SUMMARY OF THE INVENTION PROBLEMS TO BE SOLVED BY THE INVENTION

[0005] However, for ophthalmic compositions that have a reduced surfactant content or contain no surfactant and are formed into an emulsion, a method for stabilizing the emulsion has not yet been investigated.

[0006] The present invention has been made in view of the above-mentioned prior art. An object of the present invention is to provide an eye drop composition with improved temporal stability of emulsification of an oil-in-water emulsion, even when containing substantially no surfactant. MEANS FOR SOLVING THE PROBLEMS

[0007] The present inventors have found that in an eye drop composition consisting of an oil-in-water emulsion, the time-dependent stability of the emulsification of the eye drop composition consisting of an oil-in-water emulsion is improved by blending an oily component such as castor oil, sesame oil, or liquid paraffin with menthol.

[0008] The present invention provides, for example, the following [1] to [3]. [1] An eye drop composition comprising an oil-in-water emulsion, An ophthalmic composition comprising the oil-in-water emulsion containing (A) one or more selected from the group consisting of sesame oil, castor oil, and liquid paraffin, and (B) a terpenoid. [2] The ophthalmic composition according to [1], wherein the oil-in-water emulsion further comprises (C-1) a buffering agent and (C-2) one or more selected from the group consisting of vitamins A and vitamins E. [3] An ophthalmic composition comprising an oil-in-water emulsion, An ophthalmic composition comprising the oil-in-water emulsion, (C-2) one or more selected from the group consisting of vitamins A and vitamin E, and (B) a terpenoid. [4] An ophthalmic composition according to any one of [1] to [3] that is substantially free of surfactants. [5] A method for improving the time-dependent stability of an ophthalmic composition emulsion comprising (A) one or more selected from the group consisting of sesame oil, castor oil, and liquid paraffin, and (B) a mixture containing a terpenoid, wherein the mixture is irradiated with ultrasound. [6] A method for improving the time-dependent stability of the emulsification of an ophthalmic composition comprising an oil-in-water emulsion, comprising the step of irradiating a mixture containing (C-2) one or more selected from the group consisting of vitamins A and vitamin E, and (B) a terpenoid, with ultrasound. [7] The method according to [5] or [6], wherein the mixture is substantially free of a surfactant. Effects of the Invention

[0009] According to the present invention, it is possible to provide an ophthalmic composition having improved temporal stability of emulsification of an oil-in-water emulsion even without substantially containing a surfactant. Brief Description of the Drawings

[0010] [Figure 1] This is a bar graph showing the amount of change in light transmittance of Examples 1-1 to 1-3 and Comparative Examples 1-1 to 1-3. [Figure 2] This is a bar graph showing the amount of change in light transmittance of Examples 1-4 to 1-6 and Comparative Examples 1-4 to 1-6. [Figure 3] This is a bar graph showing the amount of change in light transmittance of Examples 2-1 to 2-2 and Comparative Examples 2-1 to 2-2. [Figure 4] This is a bar graph showing the amount of change in light transmittance of Examples 2-3 to 2-5 and Comparative Examples 2-3 to 2-5. [Figure 5] This is a bar graph showing the amount of change in light transmittance of Examples 3-1 to 3-2 and Comparative Examples 3-1 to 3-2. [Figure 6] This is a bar graph showing the amount of change in light transmittance of Example 4-1 and Comparative Example 4-1. [Figure 7] This is a bar graph showing the amount of change in light transmittance of Examples 5-1 to 5-3, 6-1 to 6-3 and Comparative Examples 5-1 to 5-3, 6-1 to 6-3. [Figure 8] This is a bar graph showing the amount of change in light transmittance of Examples 5-4 to 5-6 and Comparative Examples 5-4 to 5-6. [Figure 9] This is a bar graph showing the amount of change in light transmittance of Example 6-4 and Comparative Example 6-4. [Figure 10] This is a bar graph showing the amount of change in light transmittance of Examples 7-1 to 7-3 and Comparative Examples 7-1 to 7-3. Modes for Carrying Out the Invention

[0011] Hereinafter, embodiments for carrying out the present invention will be described in detail. However, the present invention is not limited to the following embodiments.

[0012] In the present specification, unless otherwise specified, the unit "%" for content means "w / v%", which is synonymous with "g / 100mL".

[0013] The ophthalmic composition according to the present embodiment consists of an oil-in-water emulsion, and the oil-in-water emulsion contains (A) one or more selected from the group consisting of sesame oil, castor oil, and liquid paraffin (also simply referred to as "component (A)"), and (B) a terpenoid (also simply referred to as "component (B)").

[0014] An ophthalmic composition according to another embodiment consists of an oil-in-water emulsion, and the oil-in-water emulsion contains (C-2) one or more selected from the group consisting of vitamin A substances and vitamin E substances, and (B) a terpenoid.

[0015] [Component (A)] The oil-in-water emulsion of the present embodiment contains one or more selected from the group consisting of sesame oil, castor oil, and liquid paraffin. As component (A), one type may be used alone, or a combination of two or more types may be used.

[0016] Sesame oil refers to a vegetable oil obtained from the seeds of plants belonging to the Sesamum genus of the Pedaliaceae family (such as Sesamum indicum Linne (Pedaliaceae)). It can be obtained from seeds using known extraction methods and known purification methods. For example, the sesame oil listed in the Japanese Pharmacopoeia (refer to the 18th Revised Japanese Pharmacopoeia Explanatory Notes C-1660 to 1662) can be obtained by purifying the oil collected by the cold pressing method.

[0017] Castor oil is a vegetable oil obtained from the seeds of plants belonging to the genus Ricinus in the family Euphorbiaceae (e.g., Ricinus communis Linne (Euphorbiaceae)). It can be obtained from the seeds using known extraction and refining methods, but for example, the castor oil listed in the Japanese Pharmacopoeia (see Commentary on the 18th Revised Japanese Pharmacopoeia C-3748~3751) is obtained by extracting the oil using a general pressing method, then centrifuging the oil residue, decolorizing it with activated clay, and finally refining it by steam distillation at high temperature (200~220°C) and high vacuum, followed by deacidification and deodorization.

[0018] Liquid paraffin is not particularly limited as long as it is pharmaceutically, pharmacologically (pharmaceutically), or physiologically acceptable. Examples of liquid paraffin include liquid paraffin and light liquid paraffin, with liquid paraffin being preferred.

[0019] (A) When sesame oil is used as an ingredient, the amount of sesame oil in the ophthalmic composition according to this embodiment may be, for example, 0.01 w / v% or more, 0.02 w / v% or more, 0.03 w / v% or more, 0.04 w / v% or more, 0.05 w / v% or more, 0.06 w / v% or more, 0.07 w / v% or more, 0.08 w / v% or more, or 0.09 w / v% or more, relative to the total amount of the ophthalmic composition.

[0020] (A) When sesame oil is used as an ingredient, the amount of sesame oil in the ophthalmic composition according to this embodiment may be, for example, 1 w / v% or less, 0.5 w / v% or less, 0.3 w / v% or less, 0.2 w / v% or less, or 0.1 w / v% or less, relative to the total amount of the ophthalmic composition.

[0021] (A) When castor oil is used as an ingredient, the amount of castor oil in the ophthalmic composition according to this embodiment may be, for example, 0.01 w / v% or more, 0.02 w / v% or more, 0.03 w / v% or more, 0.04 w / v% or more, 0.05 w / v% or more, 0.06 w / v% or more, 0.07 w / v% or more, 0.08 w / v% or more, 0.09 w / v% or more, or 0.1 w / v% or more, relative to the total amount of the ophthalmic composition.

[0022] (A) When castor oil is used as component, the amount of castor oil in the ophthalmic composition according to this embodiment may be, for example, 1 w / v% or less, 0.5 w / v% or less, 0.3 w / v% or less, 0.2 w / v% or less, or 0.15 w / v% or less, relative to the total amount of the ophthalmic composition.

[0023] (A) When liquid paraffin is used as component, the amount of liquid paraffin in the ophthalmic composition according to this embodiment may be, for example, 0.01 w / v% or more, 0.02 w / v% or more, 0.03 w / v% or more, 0.04 w / v% or more, 0.05 w / v% or more, 0.06 w / v% or more, 0.07 w / v% or more, 0.08 w / v% or more, 0.09 w / v% or more, or 0.1 w / v% or more, relative to the total amount of the ophthalmic composition.

[0024] (A) When liquid paraffin is used as component, the amount of liquid paraffin in the ophthalmic composition according to this embodiment may be, for example, 1 w / v% or less, 0.5 w / v% or less, 0.3 w / v% or less, 0.2 w / v% or less, or 0.15 w / v% or less, relative to the total amount of the ophthalmic composition.

[0025] [(B) Component] The oil-in-water emulsion according to this embodiment contains a terpenoid. The terpenoid is not particularly limited as long as it is pharmaceutically, pharmacologically (pharmaceutically) or physiologically acceptable.

[0026] Examples of terpenoids include menthol, menthone, camphor (also known as "camphor"), borneol (also known as "borneol"), geraniol, cineole, citronellol, carvone, anethole, eugenol, limonene, linalool, linalyl acetate, thymol, cymene, terpineol, pinene, camphene, isoborneol, fenchene, nerol, myrcene, myrcenol, linalool acetate, and lavandulol. Terpenoids may be d-isomers, l-isomers, or dl-isomers, for example, l-menthol, d-menthol, dl-menthol, dl-camphor, dl-camphor, dl-borneol, and dl-borneol. Furthermore, the term terpenoids in this specification also includes essential oils containing terpenoids (for example, eucalyptus oil, bergamot oil, peppermint oil, cool mint oil, spearmint oil, peppermint oil, fennel oil, cinnamon oil, rose oil, camphor oil, etc.).

[0027] As a terpenoid, menthol is preferred, and l-menthol is more preferred, from the viewpoint of further enhancing the effects of the present invention.

[0028] (B) If the ingredient contains menthol, an essential oil containing menthol may be used. Examples of such essential oils include peppermint oil, cool mint oil, spearmint oil, and peppermint oil.

[0029] You can also use commercially available menthol. You may use one type of menthol alone, or two or more types in combination.

[0030] The terpenoid content in the ophthalmic composition according to this embodiment may be, for example, 0.0001 w / v% or more, 0.0005 w / v% or more, 0.001 w / v% or more, 0.002 w / v% or more, 0.003 w / v% or more, 0.004 w / v% or more, 0.005 w / v% or more, 0.006 w / v% or more, 0.007 w / v% or more, 0.008 w / v% or more, 0.009 w / v% or more, or 0.01 w / v% or more, relative to the total amount of the ophthalmic composition.

[0031] The terpenoid content in the ophthalmic composition according to this embodiment may be, for example, 1 w / v% or less, 0.1 w / v% or less, 0.09 w / v% or less, 0.08 w / v% or less, 0.07 w / v% or less, 0.06 w / v% or less, 0.05 w / v% or less, or 0.045 w / v% or less, relative to the total amount of the ophthalmic composition.

[0032] (B) When menthol is used as component, the menthol content in the ophthalmic composition according to this embodiment may be, for example, 0.0001 w / v% or more, 0.0005 w / v% or more, 0.001 w / v% or more, 0.002 w / v% or more, 0.003 w / v% or more, 0.004 w / v% or more, 0.005 w / v% or more, 0.006 w / v% or more, 0.007 w / v% or more, 0.008 w / v% or more, 0.009 w / v% or more, or 0.01 w / v% or more, relative to the total amount of the ophthalmic composition.

[0033] (B) When menthol is used as component, the menthol content in the ophthalmic composition according to this embodiment may be, for example, 1 w / v% or less, 0.1 w / v% or less, 0.09 w / v% or less, 0.08 w / v% or less, 0.07 w / v% or less, 0.06 w / v% or less, 0.05 w / v% or less, or 0.045 w / v% or less, relative to the total amount of the ophthalmic composition. When an essential oil containing menthol is used as component (B), the content of the essential oil is set so that the menthol content in the blended essential oil satisfies the above content.

[0034] In the ophthalmic composition according to this embodiment, the content ratio of component (B) to component (A) is not particularly limited and is set appropriately depending on the types of components (A) and (B), the types and content of other components, the use and formulation form of the ophthalmic composition, etc. As for the content ratio of component (B) to component (A), from the viewpoint of further enhancing the effects of the present invention, for example, the total content of component (B) in the ophthalmic composition according to this embodiment is preferably 0.0001 to 10 parts by mass, more preferably 0.001 to 5 parts by mass, even more preferably 0.005 to 0.8 parts by mass, even more preferably 0.01 to 0.7 parts by mass, particularly preferably 0.05 to 0.6 parts by mass, and particularly most preferably 0.1 to 0.5 parts by mass, per 1 part by mass of the total content of component (A) contained in the ophthalmic composition according to this embodiment.

[0035] [(C) component] The oil-in-water emulsion of this embodiment may further contain, in addition to components (A) and (B), (C-1) a buffering agent and (C-2) one or more selected from the group consisting of vitamins A and vitamin E (components (C-1) and (C-2) are collectively referred to simply as "component (C)").

[0036] <(C-1) component> (buffering agent) (C-1) The buffering agent (also simply referred to as "(C-1) component") is not particularly limited as long as it is pharmaceutically, pharmacologically (pharmaceutically) or physiologically acceptable. Examples of buffering agents include borate buffers, phosphate buffers, carbonate buffers, acetate buffers, lactic acid buffers, succinate buffers, citrate buffers, Tris buffers, AMPD buffers, etc., with borate buffers, phosphate buffers, and citrate buffers being preferred.

[0037] Examples of boric acid buffers include boric acid and its salts. Examples of boric acid salts include alkali metal borate and alkaline earth metal borate. Specifically, examples include sodium borate, potassium tetraborate, potassium metaborate, ammonium borate, and borax. Boric acid and its salts may also be in hydrate form. When the eye drop composition according to this embodiment contains a combination of boric acid and its salts, a combination of boric acid and borax is preferred.

[0038] Examples of phosphate buffers include phosphoric acid and its salts (alkali metal phosphates, alkaline earth metal phosphates, etc.). Examples of phosphoric acid salts include disodium hydrogen phosphate, sodium dihydrogen phosphate, potassium dihydrogen phosphate, trisodium phosphate, tripotassium phosphate, calcium monohydrogen phosphate, and calcium dihydrogen phosphate.

[0039] Examples of citrate buffers include citric acid (including anhydrous citric acid) or its salts (alkali metal citrate, alkaline earth metal citrate, etc.). Examples of citric acid salts include sodium citrate, potassium citrate, calcium citrate, sodium dihydrogen citrate, and disodium citrate.

[0040] If the ophthalmic composition according to this embodiment contains a buffer as component (C), the buffer content in the ophthalmic composition may be 0.01 w / v% or more, 0.1 w / v% or more, 0.3 w / v% or more, 0.5 w / v% or more, 0.7 w / v% or more, or 0.9 w / v% or more, based on the total amount of the ophthalmic composition, and may be 3 w / v% or less, 2 w / v% or less, 1.8 w / v% or less, 1.5 w / v% or less, 1.2 w / v% or less, or 1 w / v% or less.

[0041] If the ophthalmic composition according to this embodiment contains boric acid as component (C), the boric acid content in the ophthalmic composition may be 0.01 w / v% or more, 0.1 w / v% or more, 0.3 w / v% or more, 0.5 w / v% or more, 0.7 w / v% or more, or 0.9 w / v% or more, based on the total amount of the ophthalmic composition, and may be 3 w / v% or less, 2 w / v% or less, 1.8 w / v% or less, 1.5 w / v% or less, 1.2 w / v% or less, or 1 w / v% or less.

[0042] When the ophthalmic composition according to this embodiment contains a combination of boric acid and its salt (for example, borax) as component (C), the content of boric acid and its salt in the ophthalmic composition according to this embodiment is not particularly limited. For example, based on the total amount of the ophthalmic composition, the content of boric acid and its salt may be 0.01 w / v% or more, 0.1 w / v% or more, 0.3 w / v% or more, 0.5 w / v% or more, 0.7 w / v% or more, or 0.9 w / v% or more per 100 mL, and may be 3 w / v% or less, 2 w / v% or less, 1.8 w / v% or less, 1.5 w / v% or less, 1.2 w / v% or less, or 1 w / v% or less.

[0043] If the ophthalmic composition according to this embodiment contains phosphoric acid and its salt (e.g., sodium dihydrogen phosphate) as component (C), the content of phosphoric acid and its salt in the ophthalmic composition according to this embodiment is not particularly limited. For example, based on the total amount of the ophthalmic composition, the content of phosphoric acid and its salt may be 0.001 w / v% or more, 0.01 w / v% or more, 0.05 w / v% or more, 0.1 w / v% or more, 0.15 w / v% or more, or 0.2 w / v% or more per 100 mL, and may be 3 w / v% or less, 2 w / v% or less, 1.5 w / v% or less, 1.2 w / v% or less, 1 w / v% or less, 0.7 w / v% or less, 0.6 w / v% or less, 0.5 w / v% or less, or 0.4 w / v% or less.

[0044] When the ophthalmic composition according to the present embodiment contains a citrate buffer as component (C), the content of the citrate buffer in the ophthalmic composition according to the present embodiment is not particularly limited. For example, based on the total amount of the ophthalmic composition, the content of the citrate buffer per 100 mL may be 0.001 w / v% or more, 0.005 w / v% or more, 0.01 w / v% or more, 0.015 w / v% or more, 0.05 w / v% or more, 0.1 w / v% or more, 0.15 w / v% or more, or 0.2 w / v% or more, and may be 3 w / v% or less, 2 w / v% or less, 1.5 w / v% or less, 1 w / v% or less, or 0.5 w / v% or less.

[0045] <Component C-2> (C-2) Vitamin As and Vitamin Es (also simply referred to as "component (C-2)") are not particularly limited as long as they are pharmaceutically, pharmacologically (pharmaceutically) or physiologically acceptable.

[0046] (Vitamin As) Vitamin As are not particularly limited as long as they are pharmaceutically, pharmacologically (pharmaceutically) or physiologically acceptable. Specific examples of Vitamin As include retinol, retinal, retinoic acid, derivatives thereof, and salts thereof.

[0047] Examples of derivatives of Vitamin As include esters with monovalent carboxylic acids such as retinol palmitate, retinol acetate, retinol butyrate, retinol propionate, retinol octylate, retinol laurate, retinol oleate, and retinol linolenate.

[0048] Examples of vitamin A salts include organic acid salts [e.g., monocarboxylic acid salts (acetate, trifluoroacetate, butyrate, palmitate, stearate, etc.), polycarboxylic acid salts (fumarate, maleate, succinate, malonate, etc.), oxycarboxylic acid salts (lactate, tartrate, citrate, etc.), organic sulfonates (methanesulfonate, toluenesulfonate, tosylate, etc.)], inorganic acid salts (e.g., hydrochloride, sulfate, nitrate, hydrobromide, phosphate, etc.), salts with organic bases (e.g., salts with organic amines such as methylamine, triethylamine, triethanolamine, morpholine, piperazine, pyrrolidine, tripyridine, picoline, etc.), and salts with inorganic bases [e.g., ammonium salts; salts with metals such as alkali metals (sodium, potassium, etc.), alkaline earth metals (calcium, magnesium, etc.), and aluminum, etc.].

[0049] As for vitamin A derivatives, retinol derivatives are preferred, esters of retinol with monovalent carboxylic acids are more preferred, retinyl palmitate and retinyl acetate are even more preferred, and retinyl palmitate is even more preferred.

[0050] For vitamin A derivatives, synthetic compounds may be used, or extracts obtained from natural sources (e.g., vitamin A oil) may be used. Vitamin A oil is a fatty oil obtained from animal tissues containing retinol, or a concentrate thereof, or a mixture of these with appropriate additions of vegetable oil. Commercially available vitamin A derivatives may also be used. Vitamin A derivatives may be used individually or in combination of two or more types.

[0051] If the ophthalmic composition according to this embodiment contains vitamin A as component (C), the vitamin A content in the ophthalmic composition may, from the viewpoint of more significantly exhibiting the effects of the present invention, be, for example, 0.1 million IU / 100mL to 100,000 IU / 100mL, 0.5 million IU / 100mL to 80,000 IU / 100mL, 10,000 IU / 100mL to 65,000 IU / 100mL, 47,000 IU / 100mL to 63,000 IU / 100mL, 48,000 IU / 100mL to 62,000 IU / 100mL, 49,000 IU / 100mL to 61,000 IU / 100mL, or 50,000 IU / 100mL based on the total amount of the ophthalmic composition. "IU" refers to the International Unit determined by the method described in the 18th Revised Japanese Pharmacopoeia Vitamin A Quantitative Method, etc. For example, the individual drug articles in the 18th revised Japanese Pharmacopoeia state that retinol acetate contains at least 2.5 million units of vitamin A per gram, and retinyl palmitate contains at least 1.5 million units of vitamin A per gram.

[0052] (Vitamin E derivatives) Vitamin E derivatives are not particularly limited as long as they are medically, pharmacologically (pharmaceutically), or physiologically acceptable. Specific examples of vitamin E derivatives include, for example, tocopherol, tocotrienol and their derivatives, and their salts. Tocopherol and tocotrienol may be α-, β-, γ-, or δ-, and may be either d-isomers or dl-isomers.

[0053] Examples of vitamin E derivatives include esters with organic acids such as tocopherol acetate, tocopherol succinate, tocopherol nicotinate, and tocopherol linolenic acid.

[0054] Examples of vitamin E salts include organic acid salts (lactate, acetate, butyrate, trifluoroacetate, fumarate, maleate, tartrate, citrate, succinate, malonate, methanesulfonate, toluenesulfonate, tosylate, palmitate, stearate, etc.), inorganic acid salts (e.g., hydrochloride, sulfate, nitrate, hydrobromide, phosphate, etc.), salts with organic bases (e.g., salts with organic amines such as methylamine, triethylamine, triethanolamine, morpholine, piperazine, pyrrolidine, amino acids, tripyridine, picoline, etc.), and salts with inorganic bases (e.g., salts with ammonium salts, alkali metals such as sodium and potassium, alkaline earth metals such as calcium and magnesium, and metals such as aluminum, etc.).

[0055] Preferred vitamin E derivatives include d-α-tocopherol, dl-α-tocopherol, β-tocopherol, γ-tocopherol, δ-tocopherol, vitamin E acetate (e.g., tocopherol acetate), vitamin E nicotinate, vitamin E succinate, and vitamin E linolenic acid, with tocopherol acetate (e.g., d-α-tocopherol acetate, dl-α-tocopherol acetate, etc.) being more preferred.

[0056] Vitamin E derivatives may be either natural or synthetic. Commercially available vitamin E derivatives can also be used. Vitamin E derivatives may be used individually or in combination of two or more types.

[0057] When the ophthalmic composition according to this embodiment contains vitamin E as component (C), the total amount of vitamin E in the ophthalmic composition is preferably 0.0001 to 0.5 w / v%, more preferably 0.001 to 0.15 w / v%, even more preferably 0.01 to 0.10 w / v%, and even more preferably 0.005 to 0.05 w / v%, based on the total amount of the ophthalmic composition.

[0058] In the ophthalmic composition according to this embodiment, the content ratio of component (C) to component (A) is not particularly limited and can be set as appropriate depending on the types of component (A) and component (C), the types and content of other components, the intended use of the ophthalmic composition, and the formulation form. As for the content ratio of component (C) to component (A), from the viewpoint of further enhancing the effects of the present invention, for example, the total content of component (C) in the ophthalmic composition according to this embodiment may be 0.0001 parts by mass or more, 0.0005 parts by mass or more, 0.001 parts by mass or more, 0.003 parts by mass or more, 0.01 parts by mass or more, 0.05 parts by mass or more, 0.1 parts by mass or more, 0.2 parts by mass or more, 0.3 parts by mass or more, 0.4 parts by mass or more, 1 part by mass or more, 5 parts by mass or more, or 10 parts by mass or more, and may be 300 parts by mass or less, 100 parts by mass or less, 50 parts by mass or less, 20 parts by mass or less, 15 parts by mass or less, 13 parts by mass or less, 10 parts by mass or less, 5 parts by mass or less, 3 parts by mass or less, 2 parts by mass or less, 1 part by mass or less, or 0.5 parts by mass or less.

[0059] The ophthalmic composition according to this embodiment may further contain inorganic salts. The inorganic salts are not particularly limited as long as they are pharmaceutically, pharmacologically (pharmaceutically) or physiologically acceptable.

[0060] Examples of inorganic salts include metal chlorides such as calcium chloride, magnesium chloride, sodium chloride, and potassium chloride; ammonium chloride; and metal sulfates such as calcium sulfate, magnesium sulfate, sodium sulfate, potassium sulfate, and ammonium sulfate.

[0061] As inorganic salts, metal chlorides are preferred, calcium chloride, magnesium chloride, sodium chloride, and potassium chloride are more preferred, and sodium chloride and potassium chloride are even more preferred.

[0062] Commercially available inorganic salts may be used. One type of inorganic salt may be used alone, or two or more types may be used in combination.

[0063] The inorganic salt content in the ophthalmic composition according to this embodiment is not particularly limited and is appropriately set depending on the type of inorganic salt, the type and content of other components, the use of the ophthalmic composition, and the formulation form. From the viewpoint of more significantly exhibiting the effects of the present invention, for example, the total inorganic salt content is preferably 0.01 to 10 w / v%, more preferably 0.05 to 5 w / v%, and even more preferably 0.1 to 1 w / v%, based on the total amount of the ophthalmic composition.

[0064] The water content in the ophthalmic composition of the present invention is usually 80 w / v% or more, more preferably 90 w / v% or more, even more preferably 95 w / v% or more, and particularly preferably 97 w / v% or more. The water contained in the ophthalmic composition of the present invention may be any type that is pharmaceutically, pharmacologically (pharmaceutically) or physiologically acceptable. For example, distilled water, tap water, purified water, sterile purified water, water for injection, distilled water for injection, etc., can be used. These definitions are based on the 18th edition of the Japanese Pharmacopoeia.

[0065] In this embodiment, the ophthalmic composition has improved stability over time because the oil-in-water emulsion contains the above-described components (A) and (B), and therefore may substantially not contain surfactants. That is, the surfactant content in the ophthalmic composition may be 0.001 w / v% or less, 0.0001 w / v% or less, or 0.00001 w / v% or less, based on the total amount of the ophthalmic composition, and the ophthalmic composition may not contain surfactants at all.

[0066] Examples of surfactants include nonionic surfactants such as polyoxyethylene polyoxypropylene glycol, polyoxyethylene hydrogenated castor oil, polyoxyethylene castor oil, tyroxapol, polyoxyethylene sorbitan fatty acid esters, and polyoxyl stearate; anionic surfactants such as polyoxyethylene alkyl ether phosphates, polyoxyethylene alkyl ether sulfates, alkylbenzene sulfonates, alkyl sulfates, and N-acyl taurine salts; and amphoteric surfactants such as lauryldimethylaminoacetic acid betaine.

[0067] The ophthalmic composition of the present invention may, in accordance with conventional methods, contain, in appropriate amounts, one or more pharmacologically active and physiologically active ingredients selected in combination, in addition to the above-mentioned components, depending on its use and formulation, as long as the effects of the present invention are not impaired. Examples of such pharmacologically active and physiologically active ingredients include the active ingredients in various pharmaceuticals listed in the 2000 edition of the General-Use Drug Manufacturing (Import) Approval Standards (supervised by the Pharmaceutical Affairs Review Research Association).

[0068] Specific examples of pharmacologically active or physiologically active ingredients include the following components:

[0069] Antihistamines or anti-allergic agents: for example, ketotifen fumarate, chlorpheniramine maleate, diphenhydramine hydrochloride, sodium cromoglycate, tranilast, pemirolast potassium, etc.

[0070] Decongestants: For example, tetrahydrozoline hydrochloride, naphazoline hydrochloride, naphazoline sulfate, epinephrine hydrochloride, ephedrine hydrochloride, methyl ephedrine hydrochloride, etc.

[0071] Fungicides: For example, acrinol, cetylpyridinium, benzalkonium chloride, benzethonium chloride, chlorhexidine hydrochloride, chlorhexidine gluconate, alkyldiaminoethylglycine hydrochloride, etc.

[0072] Vitamins: For example, pyridoxine hydrochloride, flavin adenine dinucleotide sodium, cyanocobalamin, panthenol, calcium pantothenate, etc.

[0073] Amino acids: For example, potassium aspartate, magnesium aspartate, aminoethylsulfonic acid, etc.

[0074] Anti-inflammatory agents: For example, dipotassium glycyrrhizinate, sodium azulene sulfonate, allantoin, ε-aminocaproic acid, berberine, lysozyme, pranoprofen, etc.

[0075] Astringents: For example, zinc oxide, zinc lactate, zinc sulfate, etc.

[0076] Others: For example, sodium hyaluronate, sulfamethoxazole, sodium sulfamethoxazole, neostigmine methylsulfate, etc.

[0077] Furthermore, the ophthalmic composition of the present invention may contain, in accordance with conventional methods, various additives selected appropriately and used in combination in appropriate amounts, one or more types, depending on its application and formulation, as long as the effects of the present invention are not impaired. Examples of such additives include the various additives listed in the 2007 Dictionary of Pharmaceutical Additives (edited by the Japan Pharmaceutical Additives Association). The following are some typical additives.

[0078] Thickening agents: For example, carboxyvinyl polymer, hydroxyethylcellulose, hydroxypropylmethylcellulose, methylcellulose, sodium carboxymethylcellulose, alginic acid, polyvinyl alcohol (complete or partially saponified), polyvinylpyrrolidone, macrogol, sodium chondroitin sulfate, sodium hyaluronate, etc.

[0079] Sugars: For example, glucose, cyclodextrin, etc.

[0080] Sugar alcohols: For example, xylitol, sorbitol, mannitol, etc. These may be in d-isomer, l-isomer, or dl-isomer.

[0081] Preservatives, disinfectants, or antibacterial agents: for example, alkyldiaminoethylglycine hydrochloride, sodium benzoate, ethanol, benzalkonium chloride, benzethonium chloride, chlorhexidine gluconate, chlorobutanol, sorbic acid, potassium sorbate, sodium dehydroacetate, methyl parahydroxybenzoate, ethyl parahydroxybenzoate, propyl parahydroxybenzoate, butyl parahydroxybenzoate, oxyquinoline sulfate, phenethyl alcohol, benzyl alcohol, Glokill (a trade name of Rhodia), etc.

[0082] pH adjusters: For example, hydrochloric acid, aminoethylsulfonic acid, epsilon-aminocaproic acid, acetic acid, sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide, sodium bicarbonate, sodium carbonate, triethanolamine, diisopropanolamine, sulfuric acid, phosphoric acid, polyphosphate, propionic acid, oxalic acid, gluconic acid, fumaric acid, lactic acid, tartaric acid, malic acid, succinic acid, gluconolactone, ammonium acetate, etc.

[0083] Stabilizers: For example, dibutylhydroxytoluene, trometamol, sodium formaldehyde sulfoxylate, tocopherol, sodium pyrosulfite, aluminum monostearate, glyceryl monostearate, etc.

[0084] Chelating agents: For example, ethylenediaminediacetic acid (EDDA), ethylenediaminetriacetic acid, ethylenediaminetetraacetic acid (EDTA), N-(2-hydroxyethyl)ethylenediaminetriacetic acid (HEDTA), diethylenetriaminepentaacetic acid (DTPA), etc.

[0085] The ophthalmic composition according to this embodiment can be manufactured by selecting a known manufacturing method. For example, by mixing component (A) and component (B) described above, and preparing the entire mixture with purified water, an ophthalmic composition consisting of an oil-in-water emulsion can be obtained by emulsifying the mixture using a stirrer or the like. As the stirrer, a bath-type ultrasonic irradiator, a horn-type ultrasonic irradiator, a rotary homogenizer, etc., can be used, but from the viewpoint of making the effects of the present invention even more pronounced, it is preferable to use a bath-type ultrasonic irradiator.

[0086] The ophthalmic composition according to this embodiment can be used, for example, as eye drops (also called eye solutions or eye medicines; eye drops include eye drops that can be used while wearing contact lenses), artificial tears, eye washes (also called eye washes or eye medicines; eye washes include eye washes that can be used while wearing contact lenses), and contact lens compositions [contact lens solutions, contact lens care compositions (contact lens disinfectants, contact lens preservatives, contact lens cleaning agents, contact lens cleaning and preservation agents), etc.], and is preferably used as an eye drop. Note that "contact lenses" include hard contact lenses and soft contact lenses (including both ionic and nonionic lenses, and including both silicone hydrogel contact lenses and non-silicone hydrogel contact lenses).

[0087] For packaging the ophthalmic composition of the present invention, a highly transparent plastic container is preferred. Examples of materials for such plastic containers include polycarbonate, polyethylene terephthalate, polyethylene, polypropylene, polyarylate, and polyethylene naphthalate. Containers made of polyethylene terephthalate are particularly preferred. Furthermore, it is desirable to use a sterilized container to ensure the safe use of the ophthalmic aqueous composition.

[0088] Specific examples of ophthalmic compositions in containers include, for example, eye drops (including eye drops that can be used while wearing contact lenses) filled in a container that is at least partially light-transmitting.

[0089] A method for improving the time-dependent stability of the emulsification of an ophthalmic composition consisting of an oil-in-water emulsion according to this embodiment includes the step of irradiating a mixture containing (A) one or more selected from the group consisting of sesame oil, castor oil, and liquid paraffin, and (B) a terpenoid, with ultrasound.

[0090] A method for improving the time-dependent stability of the emulsification of an ophthalmic composition comprising an oil-in-water emulsion of another embodiment includes the step of irradiating a mixture containing (C-2) one or more selected from the group consisting of vitamins A and E, and (B) terpenoids, with ultrasound.

[0091] A known method can be selected for irradiating the mixture with ultrasound. For example, ultrasound can be irradiated using a bath-type ultrasonic irradiator, a horn-type ultrasonic irradiator, a rotary homogenizer, etc. However, from the viewpoint of making the effects of the present invention even more pronounced, it is preferable to use a bath-type ultrasonic irradiator.

[0092] The frequency of the irradiated ultrasound may be 20kHz or higher, 22kHz or higher, 25kHz or higher, or 28kHz or higher, and may be 200kHz or lower, 100kHz or lower, 50kHz or lower, or 30kHz or lower. Furthermore, the frequency of the irradiated ultrasound may be 28kHz.

[0093] The output of the irradiated ultrasound may be low or high, but from the viewpoint of making the effects of the present invention even more pronounced, a high output is preferred. When the output of the ultrasound is low, it may be, for example, 50W or more, 80W or more, or 100W or more, and 200W or less, 150W or less, or 120W or less. When the output of the ultrasound is high, it may be, for example, 250W or more, 270W or more, or 290W or more, and 500W or less, 400W or less, or 350W or less.

[0094] The duration of ultrasonic irradiation is not particularly limited as long as the mixture forms an emulsion, but may be, for example, 1 minute or more, 3 minutes or more, or 5 minutes or more, and may be 15 minutes or less, or 10 minutes or less.

[0095] The mixture may contain the above-mentioned component (C), inorganic salts, pharmacologically active ingredients, physiologically active ingredients, or additives.

[0096] The above mixture may substantially contain no surfactant because the oil-in-water emulsion contains the above-mentioned components (A) and (B), thereby improving the time-dependent stability of the emulsification of the ophthalmic composition emulsion. In other words, the surfactant content in the mixture may be 0.001 w / v% or less, 0.0001 w / v% or less, or 0.00001 w / v% or less, based on the total amount of the mixture, and the mixture may not contain any surfactant at all. [Examples]

[0097] The present invention will be described more specifically below based on examples. However, the present invention is not limited to the following examples.

[0098] [Test Example 1] According to Table 1 below, the eye drops of Examples 1-1 to 1-3 and Comparative Examples 1-1 to 1-3 were emulsified using a bath-type ultrasonic irradiator, irradiated with ultrasound (28kHz, 300W) at 25°C for 7 minutes, to prepare the test solutions.

[0099] [Table 1]

[0100] (Evaluation of the change in light transmittance) Each prepared test solution was placed in a cell and stored at 40°C. For each test solution, the light transmittance was measured immediately after preparation (day 0), 10 days after preparation (day 10), and 20 days after preparation (day 20). The change in light transmittance (%) was calculated as the difference between the light transmittance 10 or 20 days after preparation and the light transmittance immediately after preparation. Light transmittance was measured using a UV-Vis spectrophotometer (V-630, JASCO) to measure the transmittance of light at a wavelength of 700 nm. A smaller change in light transmittance (%) indicates less change in the emulsion state, and therefore, high emulsion stability is judged to be indicated.

[0101] Figure 1 is a bar graph showing the change in light transmittance for the eye drops of Examples 1-1 to 1-3 and Comparative Examples 1-1 to 1-3. The eye drops of Examples 1-1 to 1-3 showed smaller changes in light transmittance 10 and 20 days after preparation of the test solution compared to the eye drops of Comparative Examples 1-1 to 1-3 (indicating that the emulsification stability of sesame oil, castor oil, and paraffin oil improved by adding menthol).

[0102] [Test Example 2] According to Table 2 below, the eye drops of Examples 1-4 to 1-6 and Comparative Examples 1-4 to 1-6 were emulsified using a bath-type ultrasonic irradiator by irradiating them with ultrasound (28kHz, 300W) at 25°C for 7 minutes to prepare the test solutions.

[0103] [Table 2]

[0104] Light transmittance was measured using the same method as in Example 1-1.

[0105] Figure 2 is a bar graph showing the change in light transmittance for the eye drops of Examples 1-4 to 1-6 and Comparative Examples 1-4 to 1-6. The eye drops of Examples 1-4 to 1-6 were shown to have a smaller change in light transmittance 20 days after preparation of the test solution compared to the eye drops of Comparative Examples 1-4 to 1-6.

[0106] [Test Example 3] According to Table 3 below, the eye drops of Examples 2-1 to 2-2 and Comparative Examples 2-1 to 2-2 were emulsified using a bath-type ultrasonic irradiator by irradiating them with ultrasound (28kHz, 300W) at 25°C for 7 minutes to prepare the test solutions.

[0107] [Table 3]

[0108] Light transmittance was measured using the same method as in Example 1-1.

[0109] Figures 3(A) and 3(B) are bar graphs showing the change in light transmittance for the eye drops of Examples 2-1 to 2-2 and Comparative Examples 2-1 to 2-2. The eye drops of Examples 2-1 to 2-2 were shown to have smaller changes in light transmittance 10 and 20 days after preparation of the test solution, respectively, compared to the eye drops of Comparative Examples 2-1 to 2-2.

[0110] [Test Example 4] According to Table 4 below, the eye drops of Examples 2-3 to 2-4 and Comparative Examples 2-3 to 2-4 were emulsified using a bath-type ultrasonic irradiator by irradiating them with ultrasound (28kHz, 300W) at 25°C for 7 minutes to prepare the test solutions.

[0111] [Table 4]

[0112] Light transmittance was measured using the same method as in Example 1-1.

[0113] Figure 4 is a bar graph showing the change in light transmittance for the eye drops of Examples 2-3 to 2-5 and Comparative Examples 2-3 to 2-5. The eye drops of Examples 2-3 to 2-5 were shown to have a smaller change in light transmittance 20 days after preparation compared to the eye drops of Comparative Examples 2-3 to 2-5.

[0114] [Test Example 5] According to Table 5 below, the eye drops of Examples 3-1 to 3-2 and Comparative Examples 3-1 to 3-2 were emulsified using a bath-type ultrasonic irradiator, irradiated with ultrasound (28kHz, 300W) at 25°C for 7 minutes, to prepare the test solutions.

[0115] [Table 5]

[0116] Light transmittance was measured using the same method as in Example 1-1.

[0117] Figure 5 is a bar graph showing the change in light transmittance for the eye drops of Examples 3-1 to 3-2 and Comparative Examples 3-1 to 3-2. The eye drops of Examples 3-1 to 3-2 were shown to have a smaller change in light transmittance 10 days after preparation compared to the eye drops of Comparative Examples 3-1 to 3-2.

[0118] [Test Example 6] According to Table 6 below, the eye drops of Examples 4-1 to 4-2 and Comparative Examples 4-1 to 4-2 were emulsified using a bath-type ultrasonic irradiator by irradiating them with ultrasound (28kHz, 300W) at 25°C for 7 minutes to prepare the test solutions.

[0119] [Table 6]

[0120] Light transmittance was measured using the same method as in Example 1-1.

[0121] Figures 6(A) and 6(B) are bar graphs showing the change in light transmittance for the eye drops of Example 4-1 and Comparative Example 4-1. The eye drops of Example 4-1 showed a smaller change in light transmittance 10 and 20 days after preparation of the test solution compared to the eye drops of Comparative Example 4-1.

[0122] [Test Example 7] According to Table 7 below, the eye drops of Examples 5-1 to 5-3 and Comparative Examples 5-1 to 5-3 were emulsified using a bath-type ultrasonic irradiator, irradiated with ultrasound (28kHz, 300W) at 25°C for 10 minutes, to prepare the test solutions. Unless otherwise specified, the units in Table 7 are w / v%.

[0123] [Table 7]

[0124] Light transmittance was measured using the same method as in Example 1-1.

[0125] Figures 7(A) and 7(B) are bar graphs showing the change in light transmittance for the eye drops of Examples 5-1 to 5-3 and Comparative Examples 5-1 to 5-3. The eye drops of Examples 5-1 to 5-3 were shown to have smaller changes in light transmittance 10 and 20 days after preparation of the test solution compared to the eye drops of Comparative Examples 5-1 to 5-3.

[0126] [Test Example 8] According to Table 8 below, the eye drops of Examples 5-4 to 5-6 and Comparative Examples 5-4 to 5-6 were emulsified using a bath-type ultrasonic irradiator, irradiated with ultrasound (28kHz, 300W) at 25°C for 10 minutes, to prepare the test solutions. Unless otherwise specified, the units in Table 8 are w / v%.

[0127] [Table 8]

[0128] Light transmittance was measured using the same method as in Example 1-1.

[0129] Figure 8 is a bar graph showing the change in light transmittance for the eye drops of Examples 5-4 to 5-6 and Comparative Examples 5-4 to 5-6. The eye drops of Examples 5-4 to 5-6 were shown to have a smaller change in light transmittance 20 days after preparation of the test solution compared to the eye drops of Comparative Examples 5-4 to 5-6.

[0130] [Test Example 9] According to Table 9 below, the eye drops of Examples 6-1 to 6-3 and Comparative Examples 6-1 to 6-3 were emulsified using a bath-type ultrasonic irradiator by irradiating them with ultrasound (28kHz, 300W) at 25°C for 10 minutes to prepare the test solutions.

[0131] [Table 9]

[0132] Light transmittance was measured using the same method as in Example 1-1.

[0133] Figures 7(C) and 7(D) are bar graphs showing the change in light transmittance for the eye drops of Examples 6-1 to 6-3 and Comparative Examples 6-1 to 6-3. The eye drops of Examples 6-1 to 6-3 were shown to have smaller changes in light transmittance 10 and 20 days after preparation of the test solution compared to the eye drops of Comparative Examples 6-1 to 6-3.

[0134] [Test Example 10] According to Table 10 below, the eye drops of Example 6-4 and Comparative Example 6-4 were emulsified using a bath-type ultrasonic irradiator by irradiating them with ultrasound (28kHz, 300W) at 25°C for 10 minutes to prepare the test solutions.

[0135] [Table 10]

[0136] Light transmittance was measured using the same method as in Example 1-1.

[0137] Figure 9 is a bar graph showing the change in light transmittance for the eye drops of Example 6-4 and Comparative Example 6-4. The eye drops of Example 6-4 showed a smaller change in light transmittance 20 days after preparation of the test solution compared to the eye drops of Comparative Example 6-4.

[0138] [Test Example 11] According to Table 11 below, the eye drops of Examples 7-1 to 7-3 and Comparative Examples 7-1 to 7-3 were emulsified using a bath-type ultrasonic irradiator, irradiated with ultrasound (28kHz, 300W) at 25°C for 7 minutes, to prepare the test solutions. Unless otherwise specified, the units in Table 11 are w / v%.

[0139] [Table 11]

[0140] Light transmittance was measured using the same method as in Example 1-1.

[0141] Figure 10 is a bar graph showing the change in light transmittance for the eye drops of Examples 7-1 to 7-3 and Comparative Examples 7-1 to 7-3. The eye drops of Examples 7-1 to 7-3 were shown to have a smaller change in light transmittance 20 days after preparation of the test solution compared to the eye drops of Comparative Examples 7-1 to 7-3.

[0142] [Test Example 12] In the composition of Test Example 1, eye drops (Examples 8-1 to 8-4, Comparative Examples 8-1 to 8-4) were prepared by substituting 10,000 (IU / 100mL) retinyl palmitate, 50,000 (IU / 100mL) retinyl palmitate, 0.005 w / v% tocopherol acetate, and 0.05 w / v% tocopherol acetate for sesame oil, castor oil, and liquid paraffin. Light transmittance was measured for each eye drop using the same method as in Example 1-1. The results showed that the change in light transmittance was smaller for the eye drops of Examples 8-1 to 8-4 compared to the eye drops of Comparative Examples 8-1 to 8-4 (suggesting that the emulsification stability of retinyl palmitate and tocopherol acetate is improved by adding menthol).

Claims

1. An ophthalmic composition comprising an oil-in-water emulsion, An ophthalmic composition comprising the oil-in-water emulsion containing (A) one or more selected from the group consisting of sesame oil, castor oil, and liquid paraffin, and (B) a terpenoid.

2. The ophthalmic composition according to claim 1, wherein the oil-in-water emulsion further comprises (C-1) a buffering agent and (C-2) one or more selected from the group consisting of vitamins A and vitamin E.

3. An ophthalmic composition comprising an oil-in-water emulsion, An ophthalmic composition comprising the oil-in-water emulsion (C-2) one or more selected from the group consisting of vitamins A and vitamin E, and (B) a terpenoid.

4. An ophthalmic composition according to any one of claims 1 to 3, which is substantially free of surfactants.

Citation Information

Patent Citations

  • Ophthalmic composition

    JP2002332225A

  • Emulsion

    JP2019198866A